This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharma: Fusilev Drug Sales Smash Record in June

HENDERSON, Nev. ( TheStreet) -- Spectrum Pharmaceuticals' (SPPI - Get Report) colon cancer drug Fusilev could report a mega-blowout quarter.

Fusilev sales totaled $49.7 million in June, according to monthly sales data from Wolters Kluwer released late Tuesday.

That means in June alone, Spectrum sold almost as much Fusilev as the $51 million recorded in the entire first quarter.

Spectrum won't announce second-quarter results until July 30, but Fusilev sales could top $90 million based on Wolters Kluwer monthly sales data, which have so far tracked accurately with actual, end-of-quarter reported sales.

Fusilev sales totaled $24.8 million in May and $22.3 million in April, according to Wolters Kluwer.

Spectrum continues to benefit from a shortage of generic leucovorin but now it seems doctors, particularly those in large oncology group practices, have turned to Fusilev as a permanent replacement for their colon cancer treatment regimens.

The predicted reversal in Fusilev sales growth has not materialized, even with leucovorin supply shortfalls easing somewhat. Instead, Fusilev sales continue to grow month over month with no sign of stopping.

Spectrum shares closed Tuesday at $15.63.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
SPPI $5.92 -0.67%
AAPL $131.06 -1.20%
FB $81.08 -1.00%
GOOG $554.00 -0.25%
TSLA $230.99 -0.24%

Markets

DOW 18,089.92 +51.95 0.29%
S&P 500 2,113.33 +4.41 0.21%
NASDAQ 5,057.1960 -3.05 -0.06%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs